



Name	Rina Hui	
Country	Hong Kong	
Organization	Centre of Cancer Medicine, University of Hong Kong	
Current Position	Director and Clinical Professor	

Educational Background

MBBS, PhD, FRACP

Professional Experiences & Organisations

- Clinical and research focus in lung and breast cancers
- Director of Centre of Cancer Medicine, School of Clinical Medicine, Faculty of Medicine, University of Hong Kong
- Clinical Professor, University of Hong Kong
- Honorary Consultant in Medical Oncology, Queen Mary Hospital, Hong Kong
- Senate member, University of Hong Kong
- Chair, Committee of Discontinuation, University of Hong Kong
- Advisory Board Member of HKU Primary Health Care Academy
- Clinical Director, Cancer Clinical Trials Unit, Centre of Cancer Medicine, School of Clinical Medicine, Faculty of Medicine, HKU
- Adjunct Professor, University of Sydney
- Member of Education Committee, International Association for the Study of Lung Cancer (IASLC)
- Member of the planning committee for Oncology Block, Sydney Medical School, University of Sydney
- Member of Oncology written examination committee, Sydney Medical School, University of Sydney
- Deputy chair of DIAMOND breast cancer study
- Member of the Medical Oncology Group of Australia Expert Group for lung cancer
- Member of the NSW Basic Sciences of Oncology Course Subject Matter Expert Group.
- Member of Breast Cancer Trials (Australian & New Zealand)
- Member of Thoracic Oncology Group Australasia
- Member of 9 global steering committee for 14 clinical studies
- Reviewer for highly ranked journals e.g. Annals of Oncology, Lancet Oncology
- Member of advisory board for 15 pharmaceutical companies including 7 global advisory boards

Main Scientific Publications in NSCLC

- 1) Pembrolizumab Plus Pemetrexed and Platinum in Non-Squamous Non-Small-Cell Lung Cancer: **5 Year Outcomes** From the Phase 3 KEYNOTE-189 Study. Garrasino et al, *Journal of Clinical Oncology*, 41:1992-1998, 2023.
- 2) **Five-Year Survival Outcomes** from the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Spigel et al, *Journal of Clinical Oncology*, 40:1301-1311, 2022.



- 3) **Five-Year Outcomes** with Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >50%. Reck et al, *Journal of Clinical Oncology*, 39:2339-2349, 2021.
- 4) Patient-Reported Outcomes with Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study. Hui et al, *Lancet Oncology*, 20:1670-1680, 2019.
- 5) **Five-Year Overall Survival** for Patients with Advanced Non-Small-Cell Lung Cancer Treated with Pembrolizumab: Results from the Phase 1 KEYNOTE-001 Study. Garon ... Hui et al, *Journal of Clinical Oncology*, 37:2518-2527, 2019.
- 6) Overall survival with durvalumab after chemoradiotherapy for stage III NSCLC (**Times cited: ~2,102**). Antonia et al, *New England Journal of Medicine*, 379(24):2342-2350, 2018.
- 7) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer (**Times cited: ~4,398**). Gandhi et al, *New England Journal of Medicine*, 378(22): 2078-2092, 2018.
- 8) Durvalumab after chemoradiotherapy for stage III non-small-cell lung cancer (**Times cited: ~3,189**). Antonia et al, *New England Journal of Medicine*, 377(20): 1919-1929, 2017.
- 9) Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Hui et al, *Annals of Oncology*, 28(4): 874-881, 2017.
- 10) Pembrolizumab for the treatment of non-small cell lung cancer: Efficacy, safety and identification of a PD-L1-enriched population with improved efficacy (**Times cited: ~5,560**). Garon et al, *New England Journal of Medicine*, 372(21):2018-2028, 2015.

Biography

Rina Hui is a Clinical Professor and the Director of the Centre of Cancer Medicine at the University of Hong Kong. She has a clinical and research focus on lung and breast cancers. She is a member of the Senate and the Chairperson for the Committee of Discontinuation at the University of Hong Kong.

Rina serves on the Education Committee for International Association for the Study of Lung Cancer (IASLC) and was a member of the scientific program committee for European Society of Medical Oncology Congress in 2021 and 2022. After completing her medical degree at The University of Sydney and specialist training at The Royal North Shore Hospital, Rina undertook translational research in breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree.

Before joining HKU in January 2023, Rina was a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at the Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia. She served as Co-chair of Oncology Block at the Sydney

Medical School, the University of Sydney and previously served in the written examination committee for the Royal Australasian College of Physicians. She was the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Basic Sciences of Oncology Course Subject Matter Expert Group. Rina has been principal investigator on many clinical trials, including phase I as well as many landmark practice-changing phase III clinical studies of immunotherapy and targeted therapies in lung and breast cancers over the years resulting in publications in highly ranked journals.